Pharmacists' views on the impact of the falsified medicines directive on community pharmacies: A cross-sectional survey

Simple item page
dc.contributor.authorDalton, Kieran
dc.contributor.authorConnery, Ciarán
dc.contributor.authorMurphy, Kevin D.
dc.contributor.authorO'Neill, David
dc.date.accessioned2022-12-05T14:32:16Z
dc.date.available2022-12-05T14:32:16Z
dc.date.issued2022-04-11
dc.date.updated2022-12-01T20:16:12Z
dc.description.abstractBackground: The Falsified Medicines Directive (FMD) was implemented to minimise the circulation of falsified medicines in the legal pharmaceutical supply chain. Whilst pharmacists are involved in the final step of the FMD requirements with the decommissioning of medicines at the point of supply to patients, limited research has been conducted to investigate the impact of fulfilling these requirements on the relevant stakeholders. Objective: To examine community pharmacists' views on how the FMD has affected their practice. Methods: An online survey was disseminated via email in June 2020 to pharmacists in Ireland (n = 4727), who were invited to participate if practising full time or part time in community pharmacies. Quantitative data were captured through multiple option and Likert-scale questions, and analysed using descriptive and inferential statistics. Qualitative data were captured by use of a free-text box, with the open comments analysed thematically. Results: In total, 618 valid responses were received (13.1% response rate). Most perceived that FMD requirements increased waiting times for patients (82%) and reduced time interacting with patients (65%). Only 28% agreed/strongly agreed that the introduction of the FMD legislation improves patient safety. In the open comments, the need for medicine authentication was acknowledged, but it was believed that this should be the wholesalers' responsibility, not pharmacists' responsibility. The additional step of medicines decommissioning was viewed as a time-consuming distraction to clinical checks that increased the risk for error. Pharmacists complained that they were not remunerated for the lost staff productivity or the additional software and equipment costs. Many pharmacists felt that the increased workload was disproportionate to the small risk of patients receiving falsified medicines. Conclusions: Key stakeholder engagement is required to optimise the implementation and integration of the FMD procedures into community pharmacy practice with minimal impact on dispensing and without compromising patient care.en
dc.description.statusPeer revieweden
dc.description.versionPublished Versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.articleid100127en
dc.identifier.citationDalton, K., Connery, C., Murphy, K.D., and O’Neill, D. (2022) ‘Pharmacists’ views on the impact of the Falsified Medicines Directive on community pharmacies: A cross-sectional survey’, Exploratory Research in Clinical and Social Pharmacy, 5, 100127 (8 pp). https://doi.org/10.1016/j.rcsop.2022.100127.en
dc.identifier.endpage8en
dc.identifier.journaltitleExploratory Research in Clinical And Social Pharmacyen
dc.identifier.startpage1en
dc.identifier.urihttps://hdl.handle.net/10468/13896
dc.identifier.volume5en
dc.language.isoenen
dc.publisherElsevieren
dc.relation.urihttps://doi.org/10.1016/j.rcsop.2022.100127
dc.rights© 2022 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND licenseen
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/en
dc.subjectCommunity pharmacyen
dc.subjectFalsified medicinesen
dc.subjectLegislationen
dc.subjectPatient safetyen
dc.subjectPharmacisten
dc.subjectSurveyen
dc.titlePharmacists' views on the impact of the falsified medicines directive on community pharmacies: A cross-sectional surveyen
dc.typeArticle (peer-reviewed)en
Files
Original bundle
Now showing 1 - 2 of 2
Thumbnail Image
Name:
Pharmacists'_views_on_the_impact_of_the_Falsified_Medicines_Directive_on_community_pharmacies.docx
Size:
179.41 KB
Format:
Microsoft Word XML
Description:
Author's original
Thumbnail Image
Name:
1-s2.0-S2667276622000269-main.pdf
Size:
325.31 KB
Format:
Adobe Portable Document Format
Description:
Published version
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Pharmacy - Journal Articles